




Canadian Journal of Neurological Sciences



Journal Canadien des Sciences Neurologiques

Volume 49 Number 1 January 2022




The official Journal of The Canadian Neurological Sciences Federation:

Canadian Neurological Society
Canadian Neurosurgical Society
Canadian Society of Clinical Neurophysiologists
Canadian Association of Child Neurology
Canadian Society of Neuroradiology
Canadian Stroke Consortium



CAMBRIDGE
UNIVERSITY PRESS

MOVAPO® DEMONSTRATED RAPID TREATMENT OF “OFF” EPISODES IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE^{1*}



Statistically significant improvement in UPDRS Motor scores (change from baseline) at 20 minutes with Movapo® vs. placebo ($p < 0.0001$).[†]

Movapo® is indicated for the acute, intermittent treatment of hypomobility, “OFF” episodes (“end-of-dose wearing off” and unpredictable “ON OFF” episodes) in patients with advanced Parkinson’s disease.¹

Clinical Use:

- Movapo® is a subcutaneous injection, given as an adjunct to oral medications, and must not be administered intravenously.
- Initiate treatment with use of a concomitant antiemetic, in a clinical setting where blood pressure and pulse can be closely monitored.
- Extra caution in patients > 65 years due to potential age-related comorbidities and increased frequency of certain adverse events.
- Not recommended in patients < 18 years of age.

Contraindications:

- Using concomitant drugs of the 5HT₃ antagonist class, including antiemetics in this class
- Using concomitant antihypertensive medications or vasodilators
- In patients with severe hepatic or renal impairment

Most Serious Warnings and Precautions:

Sudden Onset of Sleep: Sudden onset of sleep has occurred without warning signs, in patients on Movapo® and other dopamine agents, during activities of daily living including driving a motor vehicle. These events are **not** limited to initiation of therapy and patients should not drive or engage in activities where impaired alertness could put themselves and others at risk of serious injury or death. If drowsiness or sudden onset of sleep occurs, patients should immediately contact their physician.

Other Relevant Warnings and Precautions:

- Increased risk of falling
- Patients should not consume alcohol
- May cause postural/orthostatic hypotension
- Risk of syncope in patients with a history of postural/orthostatic hypotension, syncope, and severe cardiovascular disease
- Patients may experience coronary events or exacerbation of coronary and cerebral ischemia

- Possible QTc prolongation and potential proarrhythmic effects
- Severe nausea and vomiting at recommended doses; use with a concomitant antiemetic
- In patients with a sulfite sensitivity, may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes
- May cause dyskinesia or exacerbate pre-existing dyskinesia
- Rapid dose reduction, withdrawal, or antiparkinsonian therapy changes may cause symptoms resembling neuroleptic malignant syndrome
- May cause somnolence
- Increased susceptibility to retinal atrophy/degeneration in human albinos compared to normally pigmented people cannot be excluded
- Unknown whether non-ergot derived dopamine agonists can cause fibrotic complications
- Not recommended in patients with a major psychotic disorder
- Patients may experience hallucinations, new or worsening mental status, and behavioral changes
- Possible impulse control disorders including compulsive behaviours/intense urges
- May cause prolonged painful erections
- Monitor for melanomas
- Risk of injection site reactions
- Use during pregnancy only if the potential benefit justifies the potential risk to the fetus
- Breast-feeding is not recommended
- Mild and moderate hepatic and renal impairment

For more information:

Please consult the Product Monograph at http://www.paladin-labs.com/our_products/Movapo_en.pdf for important information relating to adverse reactions, drug interactions, and dosing information that have not been discussed in this piece. The Product Monograph is also available by calling us at 1-888-867-7426.

PD: Parkinson’s disease; UPDRS: Unified Parkinson’s Disease Rating Scale.

* Randomized, double-blind trial in 62 patients using Movapo® for at least 3 months. Hypomobile patients (on usual PD meds) were randomized to (1) Movapo® at usual maintenance dose (2–10 mg), (2) placebo at matching Movapo® volume, (3) Movapo® at usual dose + 2 mg, (4) placebo at matching Movapo® volume + 2 mg. The recommended starting dose of Movapo® is 0.2 mL (2 mg), titrated on the basis of effectiveness and tolerance, up to a maximum dose of 0.6 mL (6 mg). Individual doses above 0.6 mL are not recommended. Total daily dose should not exceed 2 mL (20 mg).

† Part III of the UPDRS was the primary outcome assessment measure; it contains 14 items designed to assess the severity of the cardinal motor findings in patients with Parkinson’s Disease.

‡ UPDRS Motor Scores: 40.6 (placebo) and 42.0 (Movapo®) at baseline, and -7.4 and -24.2 mean change from baseline at 20 minutes ($p < 0.0001$).

Reference: 1. Movapo® Product Monograph. Paladin Labs Inc. November 21, 2016.



Movapo® is a registered trademark of Britannia Pharmaceuticals Limited.
© 2021 Paladin Labs Inc., St-Laurent, QC
1-888-867-7426. www.paladin-labs.com

MOVAPPO®
apomorphine hydrochloride injection

EDITORIALS

- 1** GBS and COVID-19: Untangling the Knots
Monica Alcantara, Hans D. Katzberg
- 3** Role of Vitamins in Advanced Therapy for Parkinson's Disease: Decoding the Paradox
Jacky Ganguly, Mellany Tuesta Bernaola, Mandar Jog
- 5** Biomarkers and Alzheimer's Disease: What Will the Future Bring for 'The Worried Well'?
Luis Fornazzari, Corinne E. Fischer

REVIEW ARTICLES

- 7** Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management
Monica Alcantara, Michelle M. Mezei, Steven K. Baker, Ari Breiner, Priya Dhawan, Amanda Fiander, Nowell M. Fine, Christopher Hahn, Hans D. Katzberg, Shahin Khayambashi, Rami Massie, Genevieve Matte, Brendan Putko, Zaeem Siddiqi, Diego Delgado, Vera Bril
- 19** Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel
Jennifer Taher, Taline Naranian, Yu-Yan Poon, Aristide Merola, Tiago Mestre, Oksana Suchowersky, Vathany Kulasingam, Alfonso Fasano
- 29** Dystonia in Performing Artists: Beyond Focal Hand Dystonia
Somdattaa Ray, Pramod K. Pal

ORIGINAL ARTICLES

- 38** Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review
Mohammad Aladawi, Mohamed Elfil, Baha Abu-Esheh, Deaa Abu Jazar, Ahmad Armouti, Ahmed Bayoumi, Ezequiel Piccione

- 49** Predictors of Outcome After Mechanical Thrombectomy in Stroke Patients Aged ≥ 85 Years
Laurent Derex, Julie Haesebaert, Céline Odier, Walid Alesefir, Yves Berthezène, Marielle Buisson, Nicole Daneault, Yan Deschaintre, Omer Faruk Eker, Laura Gioia, Dana Iancu, Grégory Jacquin, Fatine Karkri, Marlène Lapierre, Norbert Nighoghossian, Jean Raymond, Daniel Roy, Christian Stapf, Alain Weill, Alexandre Y. Poppe
- 55** Near-Occlusion is a Common Variant of Carotid Stenosis: Study and Systematic Review
Elias Johansson, Allan J. Fox
- 62** Management of Ruptured Intracranial Aneurysms in the Post-International Subarachnoid Aneurysm Trial Era: A Single-Centre Prospective Series
Alexander D. Wong, Rufus Alubankudi, Judith Jarrett, Thien J. Huynh, Adam A. Dmytriw, Gwynedd E. Pickett
- 70** Access to Endovascular Thrombectomy for Stroke in Rural Versus Urban Regions
Yi Yan, Kai Hu, Susan Alcock, Esseddeeg Ghrooda, Anurag Trivedi, James McEachern, Zul Kaderali, Jai Shankar
- 76** Stroke in Male-to-Female Transgenders: A Systematic Review and Meta-Analysis
Katrina Hannah D. Ignacio, Jose Danilo B. Diestro, Adrian I. Espiritu, Maria Carissa Pineda-Franks
- 84** What Happens to the Worried Well? Follow-Up of Subjective Cognitive Impairment
Margaret Sutherland, Andrew Kirk, Chandima P. Karunanayake, Megan E. O'Connell, Debra G. Morgan
- 93** Clinical Study of 668 Indian Subjects with Juvenile, Young, and Early Onset Parkinson's Disease
Prashanth L. Kukkle, Vinay Goyal, Thenral S. Geetha, Kandadai R. Mridula, Hrishikesh Kumar, Rupam Borgohain, Adreesh Mukherjee, Pettarusp M. Wadia, Ravi Yadav, Soaham Desai, Niraj Kumar, Ravi Gupta, Atanu Biswas, Pramod K. Pal, Uday Muthane, Shymal K. Das, Niall Quinn, Vedam L. Ramprasad, the Parkinson Research Alliance of India (PRAI)

- 102** Claw Toe: Anatomic Guide for Injection of Botulinum Toxin into Foot Muscles

Toru Takekawa, Satoshi Takagi, Tomohide Kitajima, Tomoharu Sato, Kazuo Kinoshita, Masahiro Abo

- 109** Factors Associated with Quality of Life in Adults with Persistent Post-Concussion Symptoms

Nadejda Popov, Leah J. Mercier, Regan King, Tak Fung, Chantel T. Debert

NEUROIMAGING HIGHLIGHTS

- 118** Symptomatic Internal Carotid Artery Vasa Vasorum Treated With Surgical Occlusion

Christine Hawkes, Craig Durant, Brian van Adel

- 120** Spinal Intradural Phosphaturic Mesenchymal Tumor

Golmehr Sistani, Yasmine Sallam, Wai P. Ng, Andrew E. Leung, Lee Cyn Ang, Manas Sharma

BRIEF COMMUNICATIONS

- 123** Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia

Pei Huang, Yuan-Yuan Li, Jung E. Park, Ping Huang, Qin Xiao, Ying Wang, Sheng Chen, Sheng-Di Chen, Jun Liu, Yi-Wen Wu

PRACTICE PEARLS

- 129** Epidural Contrast Staining in High Cervical Micro-Arteriovenous Fistulae

Marlise P. dos Santos, Charles Haw, Fabio Settecase, Jason Chew

LETTERS TO THE EDITOR

- 133** Multiple Immune-Related Adverse Event Overlap in Two Patients Treated with Pembrolizumab

Jessica D. Jenkins, Carlos Camara-Lemarroy, Jeffrey T. Joseph, Tyson Brust

- 136** Segmental Myoclonus and Epilepsy in a Child with GAD 65 Antibodies

Michael S. Salman, Qi Xu, Martin Bunge, Werner Ilse, Kerstin Gerhold, Sean J. Udow

- 140** CT Perfusion and EEG Patterns in Contrast-Induced Encephalopathy Stroke Mimic

Giovanni Furlanis, Paolo Manganotti, Miloš Ajčević, Jessica Rossi, Chiara Vincenzi, Marcello Naccarato, Guido Bigliardi, Andrea Zini

- 144** Torsional Nystagmus and Oscillopsia as Initial Presentation of Balo's Concentric Sclerosis

Trishal Jeeva-Patel, Edward Margolin

- 146** Concurrent Carotid Endarterectomy and Flow Diverting for Supraclinoid Artery Aneurysm

Ruba Kiwan, Alistair Jukes, Burnett Johnston, Melfort Boulton

- 149** Isolated Horner Syndrome as the Only Manifestation of a Large Intrathoracic Schwannoma

Prima Moinul, Ryan Rebello, Amadeo R. Rodriguez

- 151** Acephalgic Intracranial Hypotension: Subdural Haematoma Resolution After Blood Patch

Mohamed Reda Bensaidane, Philippe Beauchemin

- 154** Botulism-like Syndrome Following Botulinum-A Injection for Hyperhidrosis and Fluoroquinolone Use

Ryan Verity, Kerri Schellenberg

- 157** Disability Assessment in Acute Ischemic Stroke: Which Score/Instrument Is Better?

Prateek Kumar Panda, Indar Kumar Sharawat

- 159** Response to Letter About 'Disability Assessment in Acute Ischemic Stroke: Which Score/instrument Is Better?'

Qian Wu, Yan Shi

COVER IMAGE

Canadian Guidelines for Hereditary Transthyretin Amyloidosis
Polyneuropathy Management

*Monica Alcantara, Michelle M. Mezei, Steven K. Baker,
Ari Breiner, Priya Dhawan, Amanda Fiander, Nowell M. Fine,
Christopher Hahn, Hans D. Katzberg, Shahin Khayambashi,
Rami Massie, Genevieve Matte, Brendan Putko, Zaeem Siddiqi,
Diego Delgado, Vera Bril*
See pages 13

Editor-in-Chief/Rédacteur en chef

Robert Chen TORONTO, ON

Associate Editors/Rédacteurs associés

Robert Hammond LONDON, ON
Philippe Hout MONTREAL, QC
Mahendranath Moharir TORONTO, ON
Tejas Sankar EDMONTON, AB
Manas Sharma LONDON, ON
Jeanne Teitelbaum MONTREAL, QC
Richard Wennberg TORONTO, ON

Past Editors/Anciens rédacteurs en chef

G. Bryan Young LONDON, ON
Douglas W. Zochodne CALGARY, AB
James A. Sharpe TORONTO, ON
Robert G. Lee CALGARY, AB
Robert T. Ross WINNIPEG, MB
(Emeritus Editor, Founding Editor)

Editorial Board/Comité éditorial

Jorge Burneo, LONDON, ON
Jodie Burton, CALGARY, AB
Colin Chalk, MONTREAL, QC
K. Ming Chan, EDMONTON, AB
Alan Goodridge, ST. JOHN'S, NL
Mark Hamilton, CALGARY, AB
Michael Hill, CALGARY, AB
Alan C. Jackson, WINNIPEG, MB
Draga Jichici, HAMILTON, ON
Suneil Kalia, TORONTO, ON
Daniel Keene, OTTOWA, ON
Julia Keith, TORONTO, ON
Nir Lipsman, TORONTO, ON
Stephen Lownie, LONDON, ON
Jian-Qiang Lu, HAMILTON, ON
Patrick McDonald, VANCOUVER, BC
Joseph Megyesi, LONDON, ON
Tiago Mestre, OTTOWA, ON

Sarah Morrow, LONDON, ON
Michael Nicolle, LONDON, ON
Ian Parney, ROCHESTER, MN
Narayan Prasad, LONDON, ON
Alex Rajput, SASKATOON, SK
Kesh Reddy, HAMILTON, ON
Larry Robinson, TORONTO, ON
Ramesh Sahpaul, NORTH VANCOUVER, BC
Dipanka Sarma, TORONTO, ON
Madeleine Sharpe, MONTREAL, QC
Sean Symons, TORONTO, ON
Brian Toyota, VANCOUVER, BC
Brian Weinshenker, ROCHESTER, MN
Sam Wiebe, CALGARY, AB
Jefferson Wilson, TORONTO, ON
Eugene Yu, TORONTO, ON

Journal Staff/Effectif du Journal

Dan Morin CALGARY, AB
Chief Executive Officer
Donna Irvin CALGARY, AB
*CNSF Membership Services /
Communications Officer*

**The official journal of: / La Revue
officielle de:**

**The Canadian Neurological Society
La Société Canadienne de Neurologie**
**The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie**
**The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique**
**The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique**
**The Canadian Society of Neuroradiology
La Société Canadienne de Neuroradiologie**
**Canadian Stroke Consortium
Consortium Neurovasculaire Canadien**

The permanent secretariat for the six societies and the Canadian Neurological Sciences Federation is at:

Le secrétariat des six associations et de la Fédération des sciences neurologiques du Canada est situé en permanence à :

143N – 8500 Macleod Trail SE
Calgary, Alberta T2H 2N1 Canada
CNSF (403) 229-9544
Fax (403) 229-1661

The Canadian Journal of Neurological Sciences is published bi-monthly. The annual subscription rate for Individuals (electronic) is £157/US\$258. The annual subscription rate for Institutions (electronic) is £207/US\$344. See <cambridge.org/cjn> for full details including taxes; e-mail: subscriptions_newyork@cambridge.org. Send address changes to Journals Fulfillment Department, Cambridge University Press, One Liberty Plaza, New York, NY 10006 USA; usmemberservices@cambridge.org. The Canadian Journal of Neurological Sciences is included in the Cambridge Core service, which can be accessed at cambridge.org/cjn. For information on other Cambridge titles, visit www.cambridge.org. For advertising rates contact M. J. Mrvica Associates, 2 West Taunton Avenue, Berlin, NJ 08009; Phone: 856-768-9360; Fax: 856-753-0064; Email: mjmrivica@mrivica.com.

Le Journal Canadien des Sciences Neurologiques est publié tous les deux mois. Le prix d'abonnement annuel pour les individus (électronique) est 157\$/258US\$. Le prix d'abonnement annuel pour les établissements (électronique) est 207\$/344US\$. Veuillez consulter <cambridge.org/cjn> pour tous les détails, y compris les taxes; email: subscriptions_newyork@cambridge.org. Envoyer les changements d'adresses aux Journals Fulfillment Department, Cambridge University Press, One Liberty Plaza, New York, NY 10006 USA; usmemberservices@cambridge.org. Le Journal canadien des sciences neurologiques est inclus dans le service Cambridge Journals Online, accessible à cambridge.org/cjn. Pour plus d'informations sur les titres disponible chez Cambridge, veuillez consulter www.cambridge.org. Pour les tarifs de publicité, contacter M. J. Mrvica Associates, 2 West Taunton Avenue, Berlin, NJ 08009; Téléphone: (1)856-768-9360; Email: mjmrivica@mrivica.com.

This journal is indexed by / Cette revue est indexée par:
Adis International, ArticleFirst, BIOBASE, BioLab, BioSci, BIOSIS Previews, Centre National de la Recherche Scientifique, CSA, CurAb, CurCont, De Gruyter Saur, E-psyche, EBSCO, Elsevier, EMBASE, FRANCIS, IBZ, Internationale Bibliographie der Rezensionen Geistes- und Sozialwissenschaftlicher Literatur, MEDLINE, MetaPress, National Library of Medicine, OCLC, PE&ON, Personal Alert, PsycFIRST, PsycINFO, PubMed, Reac, RefZh, SCI, SCOPUS, Thomson Reuters, TOCprem, VINITI RAN, Web of Science.

ISSN: 0317-1671
EISSN: 2057-0155

COPYRIGHT © 2022 by CANADIAN NEUROLOGICAL SCIENCES FEDERATION. All rights reserved. No part of this publication may be reproduced, in any form or by any means, electronic, photocopying, or otherwise, without permission in writing from Cambridge University Press. Policies, request forms and contacts are available at: <http://www.cambridge.org/about-us/rights-permissions>. Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center: <http://www.copyright.com>, email: info@copyright.com.

COPYRIGHT © 2022 du CANADIAN NEUROLOGICAL SCIENCES FEDERATION. Tous droits réservés. Aucune partie de cette publication ne peut être reproduite, sous quelque forme ou par quelque procédé que ce soit, électronique ou autre, y compris la photocopie, sans l'accord écrit de Cambridge University Press. Les politiques, les formulaires de demande et les contacts sont disponibles à: <http://www.cambridge.org/about-us/rights-permissions>. La permission de copier (pour les utilisateurs aux États-Unis) est disponible auprès Copyright Clearance Center: <http://www.copyright.com>, email: info@copyright.com.